Covid-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group (500 individuals): 800 mg hydroxychlorine tablet i two separate doses daily for one week and then 200 mg tablet daily for 6 weeks. Intervention 2: Control group: 50
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 18-65 years old No symptoms of corona and no positive corona test The desire to participate in the study No symptoms of disease at the time of admission No positive test
Exclusion criteria
Exclusion criteria: History of allergy to hydroxychloroquine Contraindications for drug use include previous history of retinopathy or G6PD, LONG QT SYNDROME, porphyry Positive HIV patients Patients with autoimmune diseases (lupus-rheumatoid arthritis) BMI >40 Diabetic CKD Using medications with contraindication to use hydroxychloroquine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of mild type covid-19 (fever - cough - dyspnea- positive PCRtest)-CDC. Timepoint: weekly for 10 weeks. Method of measurement: phone interview -medical record review.;Incidence of severe type (dyspnea - chest pain or pressure - decreased level of consciousness - bruising of the lips and face and positive PCR test) based on CDC definition. Timepoint: weekly for 10 weeks. Method of measurement: phone interview -medical record review. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization need. Timepoint: Weekly to 10 weeks. Method of measurement: phone interview -medical record review.;Mechanical ventilation need. Timepoint: Weekly to 10 weeks. Method of measurement: phone interview -medical record review.;Deaths. Timepoint: Weekly to 10 weeks. Method of measurement: phone interview -medical record review. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTermeh Tarjoman
Islamic Azad University
Outcome results
None listed